American Society of Clinical Oncology highlights 2013: breast cancer and gynecological malignancies.

about

HER2 in solid tumors: more than 10 years under the microscope; where are we now?Increased utilization of fructose has a positive effect on the development of breast cancer

P2860

Q35211263-FFDB2630-2BE7-483A-9A1D-DA9A42878482 Q41997386-245C7856-64A5-4601-8FC5-8278836741B0

P2860

American Society of Clinical Oncology highlights 2013: breast cancer and gynecological malignancies.

Item

http://www.wikidata.org/entity/Q44246406

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

American Society of Clinical O ...... nd gynecological malignancies.

@en

American Society of Clinical O ...... nd gynecological malignancies.

@nl

type

Item

label

American Society of Clinical O ...... nd gynecological malignancies.

@en

American Society of Clinical O ...... nd gynecological malignancies.

@nl

prefLabel

American Society of Clinical O ...... nd gynecological malignancies.

@en

American Society of Clinical O ...... nd gynecological malignancies.

@nl

P1476

American Society of Clinical O ...... nd gynecological malignancies.

@en

P2093

Nadia Harbeck

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 3 trial of bevacizumab in ovarian cancer.

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Hairy-cell leukemia presenting as lytic bone lesions.

P304

1433-1436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.13.159

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24106894

http://www.w3.org/2001/XMLSchema#string

American Society of Clinical Oncology highlights 2013: breast cancer and gynecological malignancies.

about

P2860

P2860

American Society of Clinical Oncology highlights 2013: breast cancer and gynecological malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698